非酒精性脂肪肝中医证候要素分布的研究及调脂通脉颗粒治疗NASH的实验研究
|
摘要
本文通过文献研究、临床研究及动物实验三部分探讨了中医药对非酒精性脂肪性肝病的认识。
1.非酒精性脂肪肝中医证候要素分布的文献研究
目的：归纳总结出文献当中非酒精性脂肪肝中医证候要素的分布情况,并分析整理出本病的常见症状,为下一步的临床研究中病例观察表的制定提供,四诊信息。方法：采用回顾性研究方法,检索北京中医药大学CNKI数据库1989-2011年公开发表在全国各类医学期刊上符合非酒精性脂肪肝要求的全部文献,按照王永炎院士提出的证候要素的分类方法,运用描述性统计方法归纳文献中非酒精性脂肪肝的中医证候及证候要素分布情况。结果及结论：得到非酒精性脂肪肝的主要证型为：痰湿内阻、肝气郁结、湿热内蕴、肝郁脾虚、痰瘀互结、肝肾阴虚、气滞血瘀、瘀血阻络8种。病位类证候要素主要是肝、肾、脾,病性类证候要素主要为：内湿、痰、气郁、气滞、血瘀、内火、气虚。
2.非酒精性脂肪肝中医证候要素分布的临床研究
目的：探讨非酒精性脂肪肝中医证候要素分布规律与特征。方法：在文献调研的基础上制定临床观察表,流行病学调查收集病例后,再用因子分析法对收集的四诊信息进行统计分析,提取非酒精性脂肪肝中医证候要素分布。结果：NAFLD患者中医证型主要为：肝郁化火证、肝郁脾虚证、脾气虚证、痰湿内阻证、湿热内蕴证、血瘀证6型。证候要素中病位类要素主要为：肝、脾；病性类要素主要为：气郁、气虚、内火、痰、内湿、血瘀。结论：通过文献调研及临床研究这2种方法得到的证型名表述繁杂,差异显著；而这2种方法得到的证候要素基本相似,病位类要素主要是肝脾肾,病性类要素主要是气郁、气滞、血瘀、气虚、痰、内湿、内火。证候要素相对来说更简明扼要、直观易懂。
3.调脂通脉颗粒治疗NASH的实验研究
目的：探索性研究中药降脂药—调脂通脉颗粒是否能对NASH有降脂作用并且还不会有肝损伤的不良反应。方法：高脂饮食诱导大鼠NASH模型后,予调脂通脉颗粒灌胃治疗,对照组为复方益肝灵,治疗4w后采集标本检测肝组织病理学及TG、TC、 HDL、LDL、ALT、AST等指标的水平。结果：调脂通脉颗粒能降低NASH大鼠的血清TG、TC、LDL、ALT、AST、MDA、Ins水平,使GSH-PX活性增强,但对HDL、SOD效果不明显。结论：调脂通脉颗粒能降低NASH大鼠的血脂水平；降低转氨酶水平,改善肝功能。其发挥作用的机制可能与改善脂质代谢及高胰岛素状态、抑制脂质过氧化反应有关。
Through literature research, clinical research and animal experiment to investigate the knowledge of Chinese medicine in non-alcoholic fatty liver disease(NAFLD).
First part, the literature research of TCM syndrome elements distribution about NAFLD
Objective:summarize TCM syndrome elements distribution of NAFLD in literature, a nd sort out the common symptoms of the disease, to provide four diagnostic informat ion for making clinical cases observed table. Methods:through retrospective study, ret rieval Beijing University of Chinese Medicine CNKI database, Select all literature whi ch meet the requirements of NAFLD from1989to2011.according to the classificatio n method which was proposed by academician WangYongyan. In the end, summarize the syndrome and syndrome elements distribution of NAFLD in the literature. Results and Conclusions:the TCM syndrome of NAFLD are8types:phlegm and dampness, liver qi stagnation, dampness and heat, liver stagnation and spleen deficiency, phlegm and blood,liver and kidney yin deficiency, qi stagnation and blood stasis, and blood st asis. syndrome elements of disease locations are liver, kidney, spleen, syndrome eleme nts of disease nature are dampness, phlegm, qi stagnation, blood stasis,heat, qi deficie ncy.
Second part, the clinical research of TCM syndrome elements distribution about NAFLD.
Objective:explore the distribution of NAFLD TCM syndrome elements. Methods:make clinical cases observed table based on literature.collect cases through epidemiological investigation, then use Factor Analysis to analyse and get the TCM syndrome factors distribution of NAFLD. Results:NAFLD TCM syndrome are:liver stagnation and of the fire, liver stagnation and spleen deficiency, spleen deficiency, phlegm and dampness resistance,dampness and heat,blood stasis.syndrome elements of disease locations are liver, spleen, syndrome elements of disease nature are qi stagnation, qi deficiency, heat, dampness, phlegm,blood stasis.
Third part, animal experiment of tiaozhitongmai granule to treat NASH.
Objective:explore if tiaozhitongmai granule have the effect of lowing blood lipids,in the same time,it will not injury liver. Methods:High-fat diet make rat NASH model, then use tiaozhitongmai granule to treat by gavage. The control group treat with Yiganling tablet, after four weeks, detect liver histopathology and the level of TG、TC、HDL、LDL、ALT、AST and soon. Results:tiaozhitongmai granule can reduce the level of TG、TC、LDL、ALT、AST、 MDA、 Ins.elevate the level of GSH-PX, have little effect on HDL、SOD. Conclusions: tiaozhitongmai granule can low blood lipids of NASH rats. It can reduce transaminase levels and improve liver function., the mechanism may play a role in improving lipid metabolism and insulin status,inhibition of lipid peroxidation.
1.非酒精性脂肪肝中医证候要素分布的文献研究
目的：归纳总结出文献当中非酒精性脂肪肝中医证候要素的分布情况,并分析整理出本病的常见症状,为下一步的临床研究中病例观察表的制定提供,四诊信息。方法：采用回顾性研究方法,检索北京中医药大学CNKI数据库1989-2011年公开发表在全国各类医学期刊上符合非酒精性脂肪肝要求的全部文献,按照王永炎院士提出的证候要素的分类方法,运用描述性统计方法归纳文献中非酒精性脂肪肝的中医证候及证候要素分布情况。结果及结论：得到非酒精性脂肪肝的主要证型为：痰湿内阻、肝气郁结、湿热内蕴、肝郁脾虚、痰瘀互结、肝肾阴虚、气滞血瘀、瘀血阻络8种。病位类证候要素主要是肝、肾、脾,病性类证候要素主要为：内湿、痰、气郁、气滞、血瘀、内火、气虚。
2.非酒精性脂肪肝中医证候要素分布的临床研究
目的：探讨非酒精性脂肪肝中医证候要素分布规律与特征。方法：在文献调研的基础上制定临床观察表,流行病学调查收集病例后,再用因子分析法对收集的四诊信息进行统计分析,提取非酒精性脂肪肝中医证候要素分布。结果：NAFLD患者中医证型主要为：肝郁化火证、肝郁脾虚证、脾气虚证、痰湿内阻证、湿热内蕴证、血瘀证6型。证候要素中病位类要素主要为：肝、脾；病性类要素主要为：气郁、气虚、内火、痰、内湿、血瘀。结论：通过文献调研及临床研究这2种方法得到的证型名表述繁杂,差异显著；而这2种方法得到的证候要素基本相似,病位类要素主要是肝脾肾,病性类要素主要是气郁、气滞、血瘀、气虚、痰、内湿、内火。证候要素相对来说更简明扼要、直观易懂。
3.调脂通脉颗粒治疗NASH的实验研究
目的：探索性研究中药降脂药—调脂通脉颗粒是否能对NASH有降脂作用并且还不会有肝损伤的不良反应。方法：高脂饮食诱导大鼠NASH模型后,予调脂通脉颗粒灌胃治疗,对照组为复方益肝灵,治疗4w后采集标本检测肝组织病理学及TG、TC、 HDL、LDL、ALT、AST等指标的水平。结果：调脂通脉颗粒能降低NASH大鼠的血清TG、TC、LDL、ALT、AST、MDA、Ins水平,使GSH-PX活性增强,但对HDL、SOD效果不明显。结论：调脂通脉颗粒能降低NASH大鼠的血脂水平；降低转氨酶水平,改善肝功能。其发挥作用的机制可能与改善脂质代谢及高胰岛素状态、抑制脂质过氧化反应有关。
Through literature research, clinical research and animal experiment to investigate the knowledge of Chinese medicine in non-alcoholic fatty liver disease(NAFLD).
First part, the literature research of TCM syndrome elements distribution about NAFLD
Objective:summarize TCM syndrome elements distribution of NAFLD in literature, a nd sort out the common symptoms of the disease, to provide four diagnostic informat ion for making clinical cases observed table. Methods:through retrospective study, ret rieval Beijing University of Chinese Medicine CNKI database, Select all literature whi ch meet the requirements of NAFLD from1989to2011.according to the classificatio n method which was proposed by academician WangYongyan. In the end, summarize the syndrome and syndrome elements distribution of NAFLD in the literature. Results and Conclusions:the TCM syndrome of NAFLD are8types:phlegm and dampness, liver qi stagnation, dampness and heat, liver stagnation and spleen deficiency, phlegm and blood,liver and kidney yin deficiency, qi stagnation and blood stasis, and blood st asis. syndrome elements of disease locations are liver, kidney, spleen, syndrome eleme nts of disease nature are dampness, phlegm, qi stagnation, blood stasis,heat, qi deficie ncy.
Second part, the clinical research of TCM syndrome elements distribution about NAFLD.
Objective:explore the distribution of NAFLD TCM syndrome elements. Methods:make clinical cases observed table based on literature.collect cases through epidemiological investigation, then use Factor Analysis to analyse and get the TCM syndrome factors distribution of NAFLD. Results:NAFLD TCM syndrome are:liver stagnation and of the fire, liver stagnation and spleen deficiency, spleen deficiency, phlegm and dampness resistance,dampness and heat,blood stasis.syndrome elements of disease locations are liver, spleen, syndrome elements of disease nature are qi stagnation, qi deficiency, heat, dampness, phlegm,blood stasis.
Third part, animal experiment of tiaozhitongmai granule to treat NASH.
Objective:explore if tiaozhitongmai granule have the effect of lowing blood lipids,in the same time,it will not injury liver. Methods:High-fat diet make rat NASH model, then use tiaozhitongmai granule to treat by gavage. The control group treat with Yiganling tablet, after four weeks, detect liver histopathology and the level of TG、TC、HDL、LDL、ALT、AST and soon. Results:tiaozhitongmai granule can reduce the level of TG、TC、LDL、ALT、AST、 MDA、 Ins.elevate the level of GSH-PX, have little effect on HDL、SOD. Conclusions: tiaozhitongmai granule can low blood lipids of NASH rats. It can reduce transaminase levels and improve liver function., the mechanism may play a role in improving lipid metabolism and insulin status,inhibition of lipid peroxidation.
引文
1.范建高.中国非酒精性脂肪性肝病的流行病学[J].中国医师进修杂志,2010,33 (1)：4-6.
2. Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcholic fatty liver disease[J]. Curr Opin Gastroenterol,2008,24(3):320-327.
3.杨春波,黄可成,王大仁.现代中医消化病学[M].福州：福建科学技术出版社,2007.
4.程华焱,曾斌芳.脂肪肝中医病名的文献研究[J].新疆中医药,2008,26(6)：12-14.
5.严世芸,李其忠.新编简明中医辞典[M].北京：人民卫生出版社,2007.
6.李军祥,陈润花.非酒精性脂肪性肝病的中医药研究进展[J].现代消化及介入诊疗,2009,14(3)：180-185.
7.胡义扬.脂肪肝的中医药治疗—一个值得深入研究的课题[J].中西医结合肝病杂志,2001,11(3)：129.
8.车念聪.非酒精性脂肪性肝病的中医证治研究[J].中西医结合肝病杂志,2008, 18(5)：257-259.
9.何勇.分期辨证治疗非酒精性脂肪肝[J].中医文献杂志,2009,4：36-37.
10.何红涛.汪慰寒教授治疗脂肪肝经验[J].中华实用中西医杂志,2004；4(17)：501.
11.王灵台,陈建杰,高月球等.补肾法为主治疗慢性肝病的临床研究[J].中医药通报,2004,4(2)：26-31.
12.张谷运.关茂桧.辨治脂肪肝的经验[J].中西医结合肝病杂志,2003；13(2)：108.
13.马晓燕,司英奎,韩雪林.脂肪肝“气虚痰毒”病机假说的研究思路[J].时珍国医国药,2006,17(12)：2421-2422.
14.李卫民,李晋灵,徐湘江.从水谷精微化生、代谢探讨脂肪肝的病因病机[J].河北中医,2009,31(3)：455-456.
15.闰智勇.肝主疏泄与脂质代谢理论和实践探讨[J].中医药导报,2009,15(2)：13.
16.李卫民,李晋灵,徐湘江.从水谷精微化生、代谢探讨脂肪肝的病因病机[J].河北中医,2009,31(3)：455-456.
17.王慧英,李红梅,杨蓓,等.141例脂肪肝患者的中医体质类型分布特点及其与证候的关系[J]北京中医药大学学报,2010,33(7)：500-502.
18.范建高.糖尿病合并脂肪肝择时用药[J].健康报,2008,12,24(5).
19.段晓燕,范建高.2010.国家级脂肪性肝病诊疗进展研讨会纪要[J].胃肠病学和肝病学杂志,2010,19(6)：566-568.
20.中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗共识意见(2009,深圳)[J].中国中西医结合消化杂志,2010,18(4)：276-279.
21.李少东,李红山,胡义杨等.脂肪肝中医证型分类的文献分析[J].中西医结合肝病杂志,2006,16(4)：255.
22.魏华凤,季光,邢练军.脂肪肝辨证分型规律的初步研究[J].辽宁中医杂志,2002,29(11)：655-656.
23.郭永红,李军祥.265例非酒精性单纯性脂肪肝中医证候因子分析[J].北京中医药,2011,30(6)：48-449.
24.刘晓平.脂肪肝中医辨治四法[J].中西医结合肝病杂志,2005,15(5)：306-307.
25.尹建鹏,沈晓红,汤峥丽,等.非酒精性脂肪肝辨证分型与年龄、性别和血脂的关系[J].福建中医药,2009,40(1)：1-2.
26.吴佳,孙志广.非酒精性脂肪肝的中医研究现状及展望[J].辽宁中医药大学学报,2009,11(11)：68.
27.叶蕾.非酒精性脂肪肝肝纤维化指标与中医辨证分型相关性探讨[J].北京中医药大学学报,2004,11(2)：15-17.
28.刘守亮,苏锐,倪建峰等.非酒精性脂肪肝生化多指标与中医辨证分型的关系研究[J].临床荟萃,2007,22(12)：892-893.
29.胡小娟,熊屏,陈群.脂肪肝常见中医证型与彩色多普勒超声特征的关系[J].湖北中医杂志,2009,31(1)：15-16.
30.朱瑾,朱学葵.脂肪肝568例B超检查与中医辨证分型关系探讨[J].浙江中西医结合杂志,2003,13(3)：160.
31.李晓陵等.64例脂肪肝中医证型与CT诊断对照研究[J].中医药信息,2002,19(4)：58
32.郭季春,杜强.中医“治未病”思想在脂肪肝健康教育中的实践[J].医药论坛杂志,2011,32(4)：175-176.
33.凌曼芝.桑明合剂治疗非酒精性脂肪肝60例[J].四川中医,2007,25(7)：42.
34陈宗标,陈文慧.从中医体质论脂肪肝辨治[J].中医研究,2009, 22(2)：52-53.
35.苏经格.四君子汤加味治疗非酒精性脂肪肝临床观察[J].中国医药学报,2004,19(8)：49,
36.陈利群,王骏.逍遥散合当归芍药散治疗非酒精性脂肪性肝病临床观察[J].中国中医急症,2008,17(1)：37-40.
37.苏建超.膈下逐瘀汤治疗脂肪肝的临床观察[J].黑龙江中医药,2006 (4)：35-36.
38.谢晶日,董群,李明,等.保肝消脂冲剂治疗脂肪肝52例临床研究[J].中国医药导报,2008：5(6)：74-75.
39.童文新,尚晓泓等.降脂通络软胶囊治疗酒精性脂肪肝(气滞血瘀证)的临床研究[J].中药新药与临床药理,2010,21(6)：661.
40.尹天雷等.肝脂康胶囊对痰浊瘀结型脂肪肝的证病疗效及其相关性研究[J].中国中西医结合消化杂志,2008,17(3)：183.
41.李海军,李东等.健脾补肾中药治疗非酒精性脂肪性肝病的临床研究[J].中西医结合肝病杂志,2007,17：203-205.
42.薛敬东等.化脂复肝颗粒治疗脂肪肝124例[J].上海中医药杂志,2004,38(6)：24.
43.陈润花,李军祥.李军祥教授治疗脂肪肝经验[J].光明中医,2008,23(4)：425.
44.叶放,赵文霞.中医对非酒精性脂肪肝的研究现状[J].中国中西医结合消化杂志,2003,11(2)：60.
45.李晶,冯五金.生山楂、泽泻、莪术对大鼠脂肪肝的影响及其交互作用的实验研究[J].山西中医,2006,22(3)：57-59.
46.曹友钊,赵筠.丹参对肝纤维化和肝功能影响[J].江西医学院学报,2005,45(4)：117.
47.周世文,周宇,徐传福.药抗肝细胞损伤有效成分研究进展[J].中国医学杂志,1995,30(2)：67-68.
48.黄萍.柴胡总皂昔对Cc14诱导的大鼠肝纤维化的保护作用[J].中国医药导报,2009,6(5)：43.
49.余轶群,李军祥,姬爱冬.何首乌、三七提取物对非酒精性脂肪性肝炎大鼠肝组织PPARα、PGC-la水平的影响[J].深圳中西医结合杂志,2009,19(2)：69-80.
50.王伟芹,李亚萍,神州,等.清肝调脂饮对非酒精性脂肪性肝炎大鼠胰岛素抵抗的影响[J].临床肝胆病杂志,2011,27(5)：42-44.
51.严红梅,刘林,孟培燕等.杞蓟制剂对非酒精性脂肪性肝炎大鼠肝组织过氧化物酶体增殖物激活受体α mRNA的影响[J].实用肝脏病杂志,2010,13(5)：339-341.
52.刘婷,赵和平,段晓燕.降脂益肝冲剂对非酒精性脂肪性肝病大鼠肝脏TBP-mRNA表达的影响[J].中国现代医药杂志,2008,10(5)：11-14.
53.黎启娇.针灸治疗脂肪肝疗效观察[J].中国针灸,2004,24(4)：243-244.
54.罗云坚,余绍源,黄穗平.消化科专病中医临床诊治[M].人民卫生出版社,2000.
55.刘玉,王国顺,田兰军等.内服外治法治疗脂肪肝的临床研究[J].中国中西医结合急救杂志,2002.9(5)：299.
1. Rector RS,Thyfault JP,Wei Y,et al. Non-alcoholic fatty liver disease and the metabolic syndrome:an update[J]. World J Gastroenterol,2008,14 (2):185-192.
2. Brunt EM.Nonalcoholic steatohepatits[J].Semin LiverDis,2004,24:3-20.
3. Day CP. Non-alcoholic fatty liver disease:current concepts and management strategies[J]. Clin Med,2006,6:19-25.
4. NimanthaMarkW ilfred Alwis, Christopher Paul Day.Non-alcoholic fatty liver disease: themist gradually clears[J] Journal ofHepatology,2008,48(1):104-112.
5. Day CP. Non-alcoholic fatty liver disease:current concepts andmanagement strategies [J]. Clin Med,2006,6:19-25.
6. MaheshwariA,Thulurath PJ.Cryptogenic cirrhosis and NAFLD:are they related[J].Am JGastroentero,2006; 103(3):664.
7. Williams CD,Stengel J,Asike MI,et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis amonga largely middle-aged population utilizing ultrasound and liver biopsy:a prospective study. Gastroenterology,2011,140:124-131.
8. Powell EE, Jonsson JR, Clouston AD. Steatosis:cofactor in other liver dise-ases[J]. Hepatology,2005,42(1):5-13.
9. Pourshams A, Malekzadeh R, Monavvari A, et al. Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors [J].Gastroenterol Hepatol,2005,20(2):229-233.
10. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease:the Dionysos nutrition and liver study[J]. He-patology,2005,42(1):44-52.
11. Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of nonalc-oholic fatty liver disease among Korean adults[J]. J Gastroenterol Hepatol,2006,21:138-143.
12. BedogniG, MiglioliL, MasuttiF, eta.l Prevalence ofand risk factors for non-alcoholic fatty liver disease:the Dionysos nutrition and liver study [J]. Hepato-logy,2005,42 (1):44-52.
13.范建高,曾民德·脂肪性肝病[M].北京：人民卫生出版社,2005：101-97.
14. Wong VW,Chu WC,Wong GL,et al. Prevalence of non alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese:a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut,2011,[Epub aheadof print].
15. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in ch-ildren and adolescents [J]. Pediatrics,2006,118(4):1388-1393.
16. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoho-lic fatty liver disease:a population-based cohort study. Gastroenterology,2005,129:113-121.
17. Hui J, Kench JG, Chitturi S, et a.l Long term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C [J]. Hepatology,2003,38:420.
18. Adams LA, Sanderson S, Lindor KD, et al.The histological course of non-alcoholic fatty liver disease:a longitudinal study of 103 patients with sequenti-al liver Biopsies. J Hepatol, 2005,42:132-138.
19. Hashimoto E, Yatsuji S, Kaneda H, et a.l The characteristics and natural-history of Japanese patientswith nonalcoholic fatty liver disease[J]. HepatRes,2005,33:72-76.
20. Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease:a longitudinal study of 103 patients with sequenti-al liver biopsies[J].J Hepatol, 2005,42(1):132-138.
21. Feldstein A E,Charatcharoenwitthaya P,Treeprasertsuk S,B,et al.The natural history of non-alcoholic fatty liver disease in children:a follow-up study for up to 20 years.G ut,2009,58:1538-1544.
22. Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol,2007,13:6419-6424.
23. Fan JG, Zhu J, Li XJ, et al. Fatty liver and the metabolic syndrome amo-ng Shanghai adults. J Gastroenterol Hepatol,2005,20:1825-1832.
24. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in ch-ildren and adolescents. Pediatrics,2006,118:1388-1393.
25. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of eleva-ted amin otransferase levels in the United States. Am J Gastroenterol,2003,98:960-967.
26.王秀芝.不同年龄人群脂肪肝流行病学特征的调查分析[J].医药论坛杂志,2010,31(12)：56.
27. Chen CH,HuangMH,Yang JC,etal. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan:metabolic significance of nonalcoholic fatty liver disease in nonobese adults[J]. JClin Gastroentero,1 2006,40(8):745-752.
28. Sorrentino P,Tarantino G,Conca P,et al. Silent non-alcoholic fatty liver diseasea clinical-histological study[J]. J Hepatol,2004,41(5):751-757.
29. Chen ZW,Chen LY,Dai HL,et al. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease[J]. J Zhejiang Univ Sci B,2008,9(8):616-622.
30.李玉芳,冯晓燕,陈虹.银川市中青年体检人群中脂肪肝患病率及危险因素的分析[J].宁夏医学杂志,2009,31(2)：169-171.
31.孙光喜.威海市机关职员脂肪肝患病率及其危险因素调查[J].中国民族民间医药杂志,2010,18：48-49.
32. Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine amino- tR ansfrase among US adolescents and associated factors:NHANES 1999-2004[J]. Gastr oenterology,2007,133(6):1814-1820.
33. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States:impact of ethnicity[J]. Hepatology,2004,40(6):1387-1395.
34.霍勇,李建平.代谢综合征与心血管疾病[J].中国医刊,2005, 40(3)：5-7.
35.周北凡,武阳丰,李 莹,等.中国成人代谢综合征腰围切点的研究[J].中华心血管病杂志,2005,33(1)：81-85.
36. PaganoG, PacaniG, MussoG, et al. Nonalcoholic steatohepatitis,insulin resistance and metabolic syndrome:further evidence for an etiologic association [J]. Hepatology 2002,35(2);367-372.
37. Tarantino, Giovanni, Saldalamacchia, et al. Non-alcoholic fatty liver disease:Further expression of the metabolism syndrome. J Gastroenterol Hepatol,2007,22:293-303.
38. Jakobsen MU, Berentzen T, Sorensen TI, et al.Abdominal obesity and fatty liver[J]. Epidemiol Rev,2007,29:77.
39. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease:predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.Gastroenterology, 2001,121:91-100.
40. Suzuki A, Angulo P, Lymp J, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology,2005,41:64-71.
41. Boza C,Riquelme A,Jbanez L,et al.Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric by-pass[J].Obes Surg,2005,15(8):1148-1153.
42. Tarantino, Giovanni, Saldalamacchia, et al. Non-alcoholic fatty liver disease:Further expression of the metabolism syndrome. J Gastroenterol Hepatol,2007,22:293-303.
43. Angelico F, Del Ben M, Confi R, et al. Non-alcoholic fatty liver syndrome:A hepatic consequence of common metabolic disease. J Gastroenterol Hepatol,2003,18:588-594.
44. Assy N,Kaita K,Mymin D,et al.Fatty infiltration of liver in hyperlipidemic patients[J].Dig Dis Sci,2000,45:1929-1934.
45.向茜,张伟,李万碧等.2型糖尿病合并非酒精性脂肪肝相关因素分析[J].西部医学,2010,22(2)：249-251.
46. Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med, 2005,22:1141-1145.
47. Kotronen A, Juurinen L, Hakkarainen A, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care,2008,31:165-169.
48. Diehl AM. Fatty liver, hypertension, and the metabolism syndrome. Gut,2004,53:9 23-924.
49. Petta S,Camm C,Cabibi D,et al. Hyperuricemia is associated with histological liver damage in patients withnon-alcoholic fatty liver disease [J]. Aliment Pharmacol Ther,2011,34(7):757-766.
50. Hwang IC,Suh SY,Suh AR,et al. The relationship between normal serum uric acid and nonalcoholic fatty liver disease[J].J Korean Med Sci,2011,26 (3):386-391.
51.陆思源,钱玉琴,周颖.非酒精性脂肪肝患者血浆同型半胱氨酸水平测定及临床意义 [J].国际消化病杂志,2011,31(3)：166.
52. Iwasaki Y, Ikeda H, Araki Y et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology,2006,43:54-63.
53. Mendez-Sanchez N, Chavez-Tapia NC, Villa AR, et al. Adiponectin as a protective factor in hepatic steatosis[J].World J Gastroenterol,2005,11(12):1737-1741.
54. Okita M,Hayashi M,Sasagawa T,et al.Effect of a moderately energy-restricted diet on obese patients with fatty liver[J].Nutrition,2001,17(7-8):542-547.
55.严克贵,郑吉平等.行为生活方式等因素与脂肪肝患病关联性研究[J].现代预防医学,2009,36(1)：16-22.
56. Molloy JW,Calcagno CJ,Williams CD,et al.Association of coffee and caffeine consumption with fatty liver disease,non-alcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology,2011,[Epub ahead of print].
57. Day CP, James OF. Steatohepatitis:a tale of two"hits"[J], Gastroenterology,1998,114: 842.
58. Pirgon O,Bilgin H,Tolu I,et al.correlation of insulin sensitivity with bone mineral s tatus in obese adolescents with non.. Alcoholic fatty liver disease[J].clinendocfinol(Oxf ),2011,75(2):189-195.
59.田培营.非酒精性脂肪肝研究进展[J].同济大学学报(医学版).2006,27(9)：47.
60.宣自华,戴敏.高脂诱导非酒精性脂肪肝动物模型及其病理机制研究进展[J].安徽医药.2009,13(3)：234.
61. Kim JY, van de Wall E, Laplante M et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue[J]. J Clin Invest,2007,117(9):2621-2637.
62.高娜,严谨,袁浩泳等.脂肪细胞因子与非酒精性脂肪肝病[J].中国临床药理学与治疗学,2010,15(4)：459.
63. Huang XD, Fan Y, Zhang H, et al. Serum leptin and soluble leptin receptor in no-nalcoholic fatty liver disease[J]. World J Gastroenterol,2008,14(18):2888.
64.敬晓琴.非酒精性脂肪肝的研究进展.胃肠病学和肝病学杂志[J].2008,17(6)：510.
65.郭艳梅,王沁,祁志.细胞色素P4502E1酶与非酒精性脂肪肝的关系[J].世界华人消化杂志,2007,15(16)：1825-1829.
66. Hevener AL, Olefsky JM, Reichart D, et al. Macrophage PPARgamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones[J]. JClin Invest,2007,117(6):1658-1669.
67. Uto H, Nakanishi L, Ido A, et al. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone inhibits fat accumu-lation and fihrosis in the livers of rats fed a choline-deficient 1-amino acid-defined diet[J]. Hepatol Res,2005,32(4):235-242.
68.邵亮,李南方.脂肪因子与非酒精性脂肪肝[J].国际消化病志,2007,27(2)：132.
69.中华医学会肝病学分会脂肪肝和酒精性肝病学组.中国非酒精性脂肪性肝病诊疗指南(2010年修订版).《中国医学前沿杂志(电子版)》,2012,4(7)：4-8.
70. Sanyal AJ,Brunt EM,Kleiner DE,et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology,2011,54:344-353.
71. Zeng MD, Fan JG, Lu LG, et al. Guidelines for the diagnosis and treatment of no nalcoholic fatty liver diseases[J]. J Dig Dis,2008,9(2):108-112.
72. Farsell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region:executive summary[J]. JGastroenterol Hepatol,2007,22(6):775-777.
73. Lieber CS,Weiss DG,Morgan TR,et al.Aspartate aminotransferase to platelet ratio index in patients with alcObolic liver fibrosis[J]. Am J Gastroenterol,2006,101(7):1500-1508.
74.葛忠伟,胡杰.脂肪肝诊断的生化检测指标临床分析[J].吉林医学,2011,32 (3)：437.
75.于雷,牛俊奇.非酒精性脂肪肝研究新进展[J].中国老年病学杂志.2007,27(11)：2150.
76.张雪玲,李建绪.罗格列酮治疗非酒精性脂肪性肝炎患者疗效观察[J].中国全科医学,2009,12(64)：949.
77.勾忠平,李秀钧,吴泰相.噻唑烷二酮类药物治疗代谢综合征的系统评价[J].中国循证医学杂志,2009,9(5)：574.
78. Uygun A, KadayifciA, IsikAT, eta.lMetformin in the treatment of patients with no n-alcoholic steatohepatitis[J].AlimentPharmacolTher,2004,19:537.
79. CaldwellS,Argo C,Al-OsaimiA. Therapy ofNAFLD:Insulin sensitizing agents[J]. ClinicalGastroenterology,2006,40:61.
80.谭丽,管小琴,王倩.维生素E、亚硒酸钠对非酒精性脂肪肝作用的实验研究[J].重庆医科大学学报,2007,32(6)：606.
81. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis:high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med.2005; 142(1):37-46.
82.张启杰,周平.还原型谷胱甘肽联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝病的疗效观察[J].中国药房,2009,20(17)：1328.
83.Ramesh S, SanyalAJ. Evaluation and magnagement of non-alcoholic steatohepatitis[J]. JHepato,1 2005,42:2212.
84.林宗梅,蔡妙国,何泽宝.熊去氧胆酸治疗非酒精性脂肪肝疗效观察[J].海峡药学,2009,21(10)：147-148.
85. UzunMA,KoksaIN,AktasS,etal.The effete of ursodeoxycholic acid on liver regeneration after Partial hepatectomy in rats with Non-alcoholic fatty liver disease[J].Hepatol Res.2009,39(8):514-21.
86. Santos UN,Lanzoni VP,Szejnfeld J,et al.A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxy cholic acid.Braz J Med Biol Res,2003,36(6):723.
87. Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a comorbid factor in nonhemoch romatotic liver disease. Alcohol.2003; 30(2):137-144.
1.欧阳锜.中医病证症三联诊疗[M].北京：人民卫生出版社,1998：79-81.
2.朱文锋.中医辨证体系及“证”的规范化研究[J].天津中医,2002,19(5)：1-4.
3.朱文锋.创立以证素为核心的辨证新体系[J].湖南中医学院学报,2004,24(6)：38.
4.王永炎.完善辨证方法体系的建议[J].中医杂志,2004,45(10)：729-731.
5.王永炎,张启明,张志斌.证候要素及其靶位的提取[J].山东中医药大学学报,2006,30(1)：1-4.
6.张志斌,王永炎.证候名称及分类研究的回顾与假设的提出[J].北京中医药大学学报,2003,26(2)：6-7.
7.金楠楠,马堃.基于聚类及因子分析的功能失调性子宫出血中医证候要素研究[J].中国中药杂志,2008,33(13)：1622-1625.
8.王阶,邢雁伟等.复杂系统熵聚堆方法对1069例冠心病心绞痛证候要素提取和应证组合规律研究[J].中国中医基础医学杂志.2008,14(3)：211.
9.金香兰,张允岭等.运用因子分析探讨原发性高血压病证候要素[J].北京中医药大学学报.2011,34(2)：131.
10.王阶,李军,姚魁武等.冠心病心绞痛证候要素和冠脉病变的Logistic回归分析[J].辽宁中医杂志,2007,34(9)：1209-1211.
11.王天芳等.基于文献研究的中医证候要素研究概况.全国第十二次中医诊断学术年会论文集：271-274.
12.张启明,王永炎,张志斌等.外感病因中证候要素的提取[J].山东中医药大学学报,2005,29(5)：339-341.
13.郭蕾,王永炎,张俊龙等.关于证候因素的讨论[J].中国中西医结合杂志,2004,24(7)：643-644.
14.闫川慧,张俊龙,郭蓄等.颤振中医治疗方案的文献研究[J].辽宁中医杂志,2010(8)：1464-1465.
15.张志斌,王永炎,王志国.辫识证候要素在突发性公共卫生事件中的作用[J].北京中医药大学学报,2005,28(6)：4-7.
16.衰小琴,李玉玲.多囊卵巢综合征中医证候的现代文献研究[J].辽宁中医药大学学报2010,12(5)：39-40.
17.王天芳,于春光,等.抑郁症中医证候及证候要素分布特点的文献研究[J].中医杂志,2006,47(9)：691-693.
18.李志更,王天芳,赵燕,等.慢性肾功能衰竭常见证候与证候要素的现代丈献分析比较[J].中华中医药学刊,2007,25(1)：52-53.
19.蔡辉,毛静远.慢性心力衰竭中医辨证规律的文献分析[J].四川中医.2011,29(7)：22.
20.周景想,唐明等.2029例冠心病心绞痛中医证候特点及组合规律分析[J].中国中西医结合杂志.2011,31(6)：753.
21.申春悌,陆岩等.高血压病中医证候要素提取和命名的方法学研究[J].南京中医药大学学报.2010,26(5)：335.
22.马宏博,司国民等.血管性痴呆中医证候分布规律文献分析[J].世界中西医结合杂志.2012,7(3)：185.
23.张俊清,张军平.病毒性心肌炎中医证候要素文献研究[J].中医杂志.2011,52(13)：1141.
24.杨剑,李风森等.支气管哮喘中医证候要素提取的文献研究[J].中国民族民间医药：22.
25.孙俊波,赵璐等.基于文献的肺炎中医证候要素组合规律研究[J].中医杂志.2012,53(13)：1137.
26.陈剑明,张声生.基于经验辨证的溃疡性结肠炎常见证候及证候要素的临床研究[J].北京中医药,2011,30(6)：418.
27.陈剑明,张声生.非酒精性脂肪性肝病常见中医证候类型及证候要素的现代文献研究[J].中西医结合肝病杂志,2012,22(1)：51.
28.丁霞,师宁等.反流性食管炎中医证候分布特点的文献研究[J].中华中医药杂志(原中国医药学报).2012,27(4)：1174.
29.黎元元,高思华.基于专家观点的糖尿病证候要素提取文献分析[J].现代中西医结合杂志.2012,21(6)：571.
30.鱼浚镛,田金洲.基于中医文献的抑郁症常见证候及证候要素分布特点的研究[J].天津中医药.2012,29(3)：299.
31.王强.“证素”学说值得商榷[J].环球中医药.2011,4(1)：52-53.
1.郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002：：32-392
2.王永炎,张启明,张志斌.证候要素及其靶位的提取[J].山东中医药大学学报,2006,30(1)：1-4.
3.王永炎.完善辨证方法体系的建议[J].中医杂志,2004,45(10)：729-731.
4.王永炎,张启明,张志斌.证候要素及其靶位的提取[J].山东中医药大学学报,2006,30(1)：1-4.
5.王天芳等.基于文献研究的中医证候要素研究概况.全国第十二次中医诊断学术年会论文集：271-274.
1.中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2006年2月修订).现代消化及介入诊疗,2007,12(4)：266-268.
2.张文彤SPSS11统计分析教程(高级篇)[M].北京希望电子出版社,2002, 6：192-200.
3.郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002：：32-392.
4.国家中医药管理局.中医病证诊断疗效标准[S].南京：南京大学出版社,1995：6-11
5.李方玲.体检人群中脂肪肝患者的症状规律与舌象特征研究[D].北京：北京中医药大学,2006：35-50
1.谢晨.浅谈脂肪肝的降脂治疗[J].医学与哲学(临床决策论坛版),2007,28(1)：18.
2. RameshS,SanyalAJ.Evaluation andmagnagement of nonalcoholic steatohepatitis. JHepato, 2005,42:2-12.
3.杨惠民,盛彤,韩丽蓓.调脂通脉颗粒治疗老年高脂血症痰瘀证的临床研究[J].中华中医药杂志,2005, 20(4)：247-248.
4.范建高,方继伟,陆元善等.U230芯片动态观察非酒精性脂肪性肝病大鼠肝脏基因表达[J].中华肝脏病杂志.2005, 13(8)：597-601.
5.顾小红,张云东,冯爱娟.解偶联蛋白-2在大鼠非酒精性脂肪肝中的表达[J].世界华人消化杂志,2005,13(19)：2310-2313.
6.苏冬梅,李健等.健脾疏肝方对非酒精性脂肪性肝炎大鼠ADP、TNF-a的影响[J].北京中医药大学学报,2011,34(12)：826-829.
7.诸葛丽等.调肝化浊解毒方对N A S H大鼠的治疗作用及其机理研究[J].江苏中医药,2012,44(5)：71-74.
8.矫燕.脂肪肝与高血脂的关系[J].中国临床医药研究杂志,2008.(184)：64.
9.张有,江徐勤,袁飞.脂肪肝患者血脂及胆碱酯酶测定的临床意义[J].实验与检验医学,2008,26(5)：557-558.
10. ASPICHUETA P, PEREZ AGOTE B, PEREZ S, et al.Impaired response of VLDL lipid and ApoB secretion to endotoxin in the fasted rat liver[J]. Endotoxin Res,2006,12(3): 181-192.
11. WEISBERG S P, MCCANN D, DESAI M, et al. Obesity is associated with macrophage accumulation in adipose tissue[J]. J ClinInvest,2008,112(12):1796-1808.
12.李宏涛,陈国民.D-氨基半乳糖研究的回顾和展望[J].肝脏,2004, 9(3)：209.
2. Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcholic fatty liver disease[J]. Curr Opin Gastroenterol,2008,24(3):320-327.
3.杨春波,黄可成,王大仁.现代中医消化病学[M].福州：福建科学技术出版社,2007.
4.程华焱,曾斌芳.脂肪肝中医病名的文献研究[J].新疆中医药,2008,26(6)：12-14.
5.严世芸,李其忠.新编简明中医辞典[M].北京：人民卫生出版社,2007.
6.李军祥,陈润花.非酒精性脂肪性肝病的中医药研究进展[J].现代消化及介入诊疗,2009,14(3)：180-185.
7.胡义扬.脂肪肝的中医药治疗—一个值得深入研究的课题[J].中西医结合肝病杂志,2001,11(3)：129.
8.车念聪.非酒精性脂肪性肝病的中医证治研究[J].中西医结合肝病杂志,2008, 18(5)：257-259.
9.何勇.分期辨证治疗非酒精性脂肪肝[J].中医文献杂志,2009,4：36-37.
10.何红涛.汪慰寒教授治疗脂肪肝经验[J].中华实用中西医杂志,2004；4(17)：501.
11.王灵台,陈建杰,高月球等.补肾法为主治疗慢性肝病的临床研究[J].中医药通报,2004,4(2)：26-31.
12.张谷运.关茂桧.辨治脂肪肝的经验[J].中西医结合肝病杂志,2003；13(2)：108.
13.马晓燕,司英奎,韩雪林.脂肪肝“气虚痰毒”病机假说的研究思路[J].时珍国医国药,2006,17(12)：2421-2422.
14.李卫民,李晋灵,徐湘江.从水谷精微化生、代谢探讨脂肪肝的病因病机[J].河北中医,2009,31(3)：455-456.
15.闰智勇.肝主疏泄与脂质代谢理论和实践探讨[J].中医药导报,2009,15(2)：13.
16.李卫民,李晋灵,徐湘江.从水谷精微化生、代谢探讨脂肪肝的病因病机[J].河北中医,2009,31(3)：455-456.
17.王慧英,李红梅,杨蓓,等.141例脂肪肝患者的中医体质类型分布特点及其与证候的关系[J]北京中医药大学学报,2010,33(7)：500-502.
18.范建高.糖尿病合并脂肪肝择时用药[J].健康报,2008,12,24(5).
19.段晓燕,范建高.2010.国家级脂肪性肝病诊疗进展研讨会纪要[J].胃肠病学和肝病学杂志,2010,19(6)：566-568.
20.中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗共识意见(2009,深圳)[J].中国中西医结合消化杂志,2010,18(4)：276-279.
21.李少东,李红山,胡义杨等.脂肪肝中医证型分类的文献分析[J].中西医结合肝病杂志,2006,16(4)：255.
22.魏华凤,季光,邢练军.脂肪肝辨证分型规律的初步研究[J].辽宁中医杂志,2002,29(11)：655-656.
23.郭永红,李军祥.265例非酒精性单纯性脂肪肝中医证候因子分析[J].北京中医药,2011,30(6)：48-449.
24.刘晓平.脂肪肝中医辨治四法[J].中西医结合肝病杂志,2005,15(5)：306-307.
25.尹建鹏,沈晓红,汤峥丽,等.非酒精性脂肪肝辨证分型与年龄、性别和血脂的关系[J].福建中医药,2009,40(1)：1-2.
26.吴佳,孙志广.非酒精性脂肪肝的中医研究现状及展望[J].辽宁中医药大学学报,2009,11(11)：68.
27.叶蕾.非酒精性脂肪肝肝纤维化指标与中医辨证分型相关性探讨[J].北京中医药大学学报,2004,11(2)：15-17.
28.刘守亮,苏锐,倪建峰等.非酒精性脂肪肝生化多指标与中医辨证分型的关系研究[J].临床荟萃,2007,22(12)：892-893.
29.胡小娟,熊屏,陈群.脂肪肝常见中医证型与彩色多普勒超声特征的关系[J].湖北中医杂志,2009,31(1)：15-16.
30.朱瑾,朱学葵.脂肪肝568例B超检查与中医辨证分型关系探讨[J].浙江中西医结合杂志,2003,13(3)：160.
31.李晓陵等.64例脂肪肝中医证型与CT诊断对照研究[J].中医药信息,2002,19(4)：58
32.郭季春,杜强.中医“治未病”思想在脂肪肝健康教育中的实践[J].医药论坛杂志,2011,32(4)：175-176.
33.凌曼芝.桑明合剂治疗非酒精性脂肪肝60例[J].四川中医,2007,25(7)：42.
34陈宗标,陈文慧.从中医体质论脂肪肝辨治[J].中医研究,2009, 22(2)：52-53.
35.苏经格.四君子汤加味治疗非酒精性脂肪肝临床观察[J].中国医药学报,2004,19(8)：49,
36.陈利群,王骏.逍遥散合当归芍药散治疗非酒精性脂肪性肝病临床观察[J].中国中医急症,2008,17(1)：37-40.
37.苏建超.膈下逐瘀汤治疗脂肪肝的临床观察[J].黑龙江中医药,2006 (4)：35-36.
38.谢晶日,董群,李明,等.保肝消脂冲剂治疗脂肪肝52例临床研究[J].中国医药导报,2008：5(6)：74-75.
39.童文新,尚晓泓等.降脂通络软胶囊治疗酒精性脂肪肝(气滞血瘀证)的临床研究[J].中药新药与临床药理,2010,21(6)：661.
40.尹天雷等.肝脂康胶囊对痰浊瘀结型脂肪肝的证病疗效及其相关性研究[J].中国中西医结合消化杂志,2008,17(3)：183.
41.李海军,李东等.健脾补肾中药治疗非酒精性脂肪性肝病的临床研究[J].中西医结合肝病杂志,2007,17：203-205.
42.薛敬东等.化脂复肝颗粒治疗脂肪肝124例[J].上海中医药杂志,2004,38(6)：24.
43.陈润花,李军祥.李军祥教授治疗脂肪肝经验[J].光明中医,2008,23(4)：425.
44.叶放,赵文霞.中医对非酒精性脂肪肝的研究现状[J].中国中西医结合消化杂志,2003,11(2)：60.
45.李晶,冯五金.生山楂、泽泻、莪术对大鼠脂肪肝的影响及其交互作用的实验研究[J].山西中医,2006,22(3)：57-59.
46.曹友钊,赵筠.丹参对肝纤维化和肝功能影响[J].江西医学院学报,2005,45(4)：117.
47.周世文,周宇,徐传福.药抗肝细胞损伤有效成分研究进展[J].中国医学杂志,1995,30(2)：67-68.
48.黄萍.柴胡总皂昔对Cc14诱导的大鼠肝纤维化的保护作用[J].中国医药导报,2009,6(5)：43.
49.余轶群,李军祥,姬爱冬.何首乌、三七提取物对非酒精性脂肪性肝炎大鼠肝组织PPARα、PGC-la水平的影响[J].深圳中西医结合杂志,2009,19(2)：69-80.
50.王伟芹,李亚萍,神州,等.清肝调脂饮对非酒精性脂肪性肝炎大鼠胰岛素抵抗的影响[J].临床肝胆病杂志,2011,27(5)：42-44.
51.严红梅,刘林,孟培燕等.杞蓟制剂对非酒精性脂肪性肝炎大鼠肝组织过氧化物酶体增殖物激活受体α mRNA的影响[J].实用肝脏病杂志,2010,13(5)：339-341.
52.刘婷,赵和平,段晓燕.降脂益肝冲剂对非酒精性脂肪性肝病大鼠肝脏TBP-mRNA表达的影响[J].中国现代医药杂志,2008,10(5)：11-14.
53.黎启娇.针灸治疗脂肪肝疗效观察[J].中国针灸,2004,24(4)：243-244.
54.罗云坚,余绍源,黄穗平.消化科专病中医临床诊治[M].人民卫生出版社,2000.
55.刘玉,王国顺,田兰军等.内服外治法治疗脂肪肝的临床研究[J].中国中西医结合急救杂志,2002.9(5)：299.
1. Rector RS,Thyfault JP,Wei Y,et al. Non-alcoholic fatty liver disease and the metabolic syndrome:an update[J]. World J Gastroenterol,2008,14 (2):185-192.
2. Brunt EM.Nonalcoholic steatohepatits[J].Semin LiverDis,2004,24:3-20.
3. Day CP. Non-alcoholic fatty liver disease:current concepts and management strategies[J]. Clin Med,2006,6:19-25.
4. NimanthaMarkW ilfred Alwis, Christopher Paul Day.Non-alcoholic fatty liver disease: themist gradually clears[J] Journal ofHepatology,2008,48(1):104-112.
5. Day CP. Non-alcoholic fatty liver disease:current concepts andmanagement strategies [J]. Clin Med,2006,6:19-25.
6. MaheshwariA,Thulurath PJ.Cryptogenic cirrhosis and NAFLD:are they related[J].Am JGastroentero,2006; 103(3):664.
7. Williams CD,Stengel J,Asike MI,et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis amonga largely middle-aged population utilizing ultrasound and liver biopsy:a prospective study. Gastroenterology,2011,140:124-131.
8. Powell EE, Jonsson JR, Clouston AD. Steatosis:cofactor in other liver dise-ases[J]. Hepatology,2005,42(1):5-13.
9. Pourshams A, Malekzadeh R, Monavvari A, et al. Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors [J].Gastroenterol Hepatol,2005,20(2):229-233.
10. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease:the Dionysos nutrition and liver study[J]. He-patology,2005,42(1):44-52.
11. Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of nonalc-oholic fatty liver disease among Korean adults[J]. J Gastroenterol Hepatol,2006,21:138-143.
12. BedogniG, MiglioliL, MasuttiF, eta.l Prevalence ofand risk factors for non-alcoholic fatty liver disease:the Dionysos nutrition and liver study [J]. Hepato-logy,2005,42 (1):44-52.
13.范建高,曾民德·脂肪性肝病[M].北京：人民卫生出版社,2005：101-97.
14. Wong VW,Chu WC,Wong GL,et al. Prevalence of non alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese:a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut,2011,[Epub aheadof print].
15. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in ch-ildren and adolescents [J]. Pediatrics,2006,118(4):1388-1393.
16. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoho-lic fatty liver disease:a population-based cohort study. Gastroenterology,2005,129:113-121.
17. Hui J, Kench JG, Chitturi S, et a.l Long term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C [J]. Hepatology,2003,38:420.
18. Adams LA, Sanderson S, Lindor KD, et al.The histological course of non-alcoholic fatty liver disease:a longitudinal study of 103 patients with sequenti-al liver Biopsies. J Hepatol, 2005,42:132-138.
19. Hashimoto E, Yatsuji S, Kaneda H, et a.l The characteristics and natural-history of Japanese patientswith nonalcoholic fatty liver disease[J]. HepatRes,2005,33:72-76.
20. Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease:a longitudinal study of 103 patients with sequenti-al liver biopsies[J].J Hepatol, 2005,42(1):132-138.
21. Feldstein A E,Charatcharoenwitthaya P,Treeprasertsuk S,B,et al.The natural history of non-alcoholic fatty liver disease in children:a follow-up study for up to 20 years.G ut,2009,58:1538-1544.
22. Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol,2007,13:6419-6424.
23. Fan JG, Zhu J, Li XJ, et al. Fatty liver and the metabolic syndrome amo-ng Shanghai adults. J Gastroenterol Hepatol,2005,20:1825-1832.
24. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in ch-ildren and adolescents. Pediatrics,2006,118:1388-1393.
25. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of eleva-ted amin otransferase levels in the United States. Am J Gastroenterol,2003,98:960-967.
26.王秀芝.不同年龄人群脂肪肝流行病学特征的调查分析[J].医药论坛杂志,2010,31(12)：56.
27. Chen CH,HuangMH,Yang JC,etal. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan:metabolic significance of nonalcoholic fatty liver disease in nonobese adults[J]. JClin Gastroentero,1 2006,40(8):745-752.
28. Sorrentino P,Tarantino G,Conca P,et al. Silent non-alcoholic fatty liver diseasea clinical-histological study[J]. J Hepatol,2004,41(5):751-757.
29. Chen ZW,Chen LY,Dai HL,et al. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease[J]. J Zhejiang Univ Sci B,2008,9(8):616-622.
30.李玉芳,冯晓燕,陈虹.银川市中青年体检人群中脂肪肝患病率及危险因素的分析[J].宁夏医学杂志,2009,31(2)：169-171.
31.孙光喜.威海市机关职员脂肪肝患病率及其危险因素调查[J].中国民族民间医药杂志,2010,18：48-49.
32. Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine amino- tR ansfrase among US adolescents and associated factors:NHANES 1999-2004[J]. Gastr oenterology,2007,133(6):1814-1820.
33. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States:impact of ethnicity[J]. Hepatology,2004,40(6):1387-1395.
34.霍勇,李建平.代谢综合征与心血管疾病[J].中国医刊,2005, 40(3)：5-7.
35.周北凡,武阳丰,李 莹,等.中国成人代谢综合征腰围切点的研究[J].中华心血管病杂志,2005,33(1)：81-85.
36. PaganoG, PacaniG, MussoG, et al. Nonalcoholic steatohepatitis,insulin resistance and metabolic syndrome:further evidence for an etiologic association [J]. Hepatology 2002,35(2);367-372.
37. Tarantino, Giovanni, Saldalamacchia, et al. Non-alcoholic fatty liver disease:Further expression of the metabolism syndrome. J Gastroenterol Hepatol,2007,22:293-303.
38. Jakobsen MU, Berentzen T, Sorensen TI, et al.Abdominal obesity and fatty liver[J]. Epidemiol Rev,2007,29:77.
39. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease:predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.Gastroenterology, 2001,121:91-100.
40. Suzuki A, Angulo P, Lymp J, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology,2005,41:64-71.
41. Boza C,Riquelme A,Jbanez L,et al.Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric by-pass[J].Obes Surg,2005,15(8):1148-1153.
42. Tarantino, Giovanni, Saldalamacchia, et al. Non-alcoholic fatty liver disease:Further expression of the metabolism syndrome. J Gastroenterol Hepatol,2007,22:293-303.
43. Angelico F, Del Ben M, Confi R, et al. Non-alcoholic fatty liver syndrome:A hepatic consequence of common metabolic disease. J Gastroenterol Hepatol,2003,18:588-594.
44. Assy N,Kaita K,Mymin D,et al.Fatty infiltration of liver in hyperlipidemic patients[J].Dig Dis Sci,2000,45:1929-1934.
45.向茜,张伟,李万碧等.2型糖尿病合并非酒精性脂肪肝相关因素分析[J].西部医学,2010,22(2)：249-251.
46. Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med, 2005,22:1141-1145.
47. Kotronen A, Juurinen L, Hakkarainen A, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care,2008,31:165-169.
48. Diehl AM. Fatty liver, hypertension, and the metabolism syndrome. Gut,2004,53:9 23-924.
49. Petta S,Camm C,Cabibi D,et al. Hyperuricemia is associated with histological liver damage in patients withnon-alcoholic fatty liver disease [J]. Aliment Pharmacol Ther,2011,34(7):757-766.
50. Hwang IC,Suh SY,Suh AR,et al. The relationship between normal serum uric acid and nonalcoholic fatty liver disease[J].J Korean Med Sci,2011,26 (3):386-391.
51.陆思源,钱玉琴,周颖.非酒精性脂肪肝患者血浆同型半胱氨酸水平测定及临床意义 [J].国际消化病杂志,2011,31(3)：166.
52. Iwasaki Y, Ikeda H, Araki Y et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology,2006,43:54-63.
53. Mendez-Sanchez N, Chavez-Tapia NC, Villa AR, et al. Adiponectin as a protective factor in hepatic steatosis[J].World J Gastroenterol,2005,11(12):1737-1741.
54. Okita M,Hayashi M,Sasagawa T,et al.Effect of a moderately energy-restricted diet on obese patients with fatty liver[J].Nutrition,2001,17(7-8):542-547.
55.严克贵,郑吉平等.行为生活方式等因素与脂肪肝患病关联性研究[J].现代预防医学,2009,36(1)：16-22.
56. Molloy JW,Calcagno CJ,Williams CD,et al.Association of coffee and caffeine consumption with fatty liver disease,non-alcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology,2011,[Epub ahead of print].
57. Day CP, James OF. Steatohepatitis:a tale of two"hits"[J], Gastroenterology,1998,114: 842.
58. Pirgon O,Bilgin H,Tolu I,et al.correlation of insulin sensitivity with bone mineral s tatus in obese adolescents with non.. Alcoholic fatty liver disease[J].clinendocfinol(Oxf ),2011,75(2):189-195.
59.田培营.非酒精性脂肪肝研究进展[J].同济大学学报(医学版).2006,27(9)：47.
60.宣自华,戴敏.高脂诱导非酒精性脂肪肝动物模型及其病理机制研究进展[J].安徽医药.2009,13(3)：234.
61. Kim JY, van de Wall E, Laplante M et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue[J]. J Clin Invest,2007,117(9):2621-2637.
62.高娜,严谨,袁浩泳等.脂肪细胞因子与非酒精性脂肪肝病[J].中国临床药理学与治疗学,2010,15(4)：459.
63. Huang XD, Fan Y, Zhang H, et al. Serum leptin and soluble leptin receptor in no-nalcoholic fatty liver disease[J]. World J Gastroenterol,2008,14(18):2888.
64.敬晓琴.非酒精性脂肪肝的研究进展.胃肠病学和肝病学杂志[J].2008,17(6)：510.
65.郭艳梅,王沁,祁志.细胞色素P4502E1酶与非酒精性脂肪肝的关系[J].世界华人消化杂志,2007,15(16)：1825-1829.
66. Hevener AL, Olefsky JM, Reichart D, et al. Macrophage PPARgamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones[J]. JClin Invest,2007,117(6):1658-1669.
67. Uto H, Nakanishi L, Ido A, et al. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone inhibits fat accumu-lation and fihrosis in the livers of rats fed a choline-deficient 1-amino acid-defined diet[J]. Hepatol Res,2005,32(4):235-242.
68.邵亮,李南方.脂肪因子与非酒精性脂肪肝[J].国际消化病志,2007,27(2)：132.
69.中华医学会肝病学分会脂肪肝和酒精性肝病学组.中国非酒精性脂肪性肝病诊疗指南(2010年修订版).《中国医学前沿杂志(电子版)》,2012,4(7)：4-8.
70. Sanyal AJ,Brunt EM,Kleiner DE,et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology,2011,54:344-353.
71. Zeng MD, Fan JG, Lu LG, et al. Guidelines for the diagnosis and treatment of no nalcoholic fatty liver diseases[J]. J Dig Dis,2008,9(2):108-112.
72. Farsell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region:executive summary[J]. JGastroenterol Hepatol,2007,22(6):775-777.
73. Lieber CS,Weiss DG,Morgan TR,et al.Aspartate aminotransferase to platelet ratio index in patients with alcObolic liver fibrosis[J]. Am J Gastroenterol,2006,101(7):1500-1508.
74.葛忠伟,胡杰.脂肪肝诊断的生化检测指标临床分析[J].吉林医学,2011,32 (3)：437.
75.于雷,牛俊奇.非酒精性脂肪肝研究新进展[J].中国老年病学杂志.2007,27(11)：2150.
76.张雪玲,李建绪.罗格列酮治疗非酒精性脂肪性肝炎患者疗效观察[J].中国全科医学,2009,12(64)：949.
77.勾忠平,李秀钧,吴泰相.噻唑烷二酮类药物治疗代谢综合征的系统评价[J].中国循证医学杂志,2009,9(5)：574.
78. Uygun A, KadayifciA, IsikAT, eta.lMetformin in the treatment of patients with no n-alcoholic steatohepatitis[J].AlimentPharmacolTher,2004,19:537.
79. CaldwellS,Argo C,Al-OsaimiA. Therapy ofNAFLD:Insulin sensitizing agents[J]. ClinicalGastroenterology,2006,40:61.
80.谭丽,管小琴,王倩.维生素E、亚硒酸钠对非酒精性脂肪肝作用的实验研究[J].重庆医科大学学报,2007,32(6)：606.
81. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis:high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med.2005; 142(1):37-46.
82.张启杰,周平.还原型谷胱甘肽联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝病的疗效观察[J].中国药房,2009,20(17)：1328.
83.Ramesh S, SanyalAJ. Evaluation and magnagement of non-alcoholic steatohepatitis[J]. JHepato,1 2005,42:2212.
84.林宗梅,蔡妙国,何泽宝.熊去氧胆酸治疗非酒精性脂肪肝疗效观察[J].海峡药学,2009,21(10)：147-148.
85. UzunMA,KoksaIN,AktasS,etal.The effete of ursodeoxycholic acid on liver regeneration after Partial hepatectomy in rats with Non-alcoholic fatty liver disease[J].Hepatol Res.2009,39(8):514-21.
86. Santos UN,Lanzoni VP,Szejnfeld J,et al.A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxy cholic acid.Braz J Med Biol Res,2003,36(6):723.
87. Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a comorbid factor in nonhemoch romatotic liver disease. Alcohol.2003; 30(2):137-144.
1.欧阳锜.中医病证症三联诊疗[M].北京：人民卫生出版社,1998：79-81.
2.朱文锋.中医辨证体系及“证”的规范化研究[J].天津中医,2002,19(5)：1-4.
3.朱文锋.创立以证素为核心的辨证新体系[J].湖南中医学院学报,2004,24(6)：38.
4.王永炎.完善辨证方法体系的建议[J].中医杂志,2004,45(10)：729-731.
5.王永炎,张启明,张志斌.证候要素及其靶位的提取[J].山东中医药大学学报,2006,30(1)：1-4.
6.张志斌,王永炎.证候名称及分类研究的回顾与假设的提出[J].北京中医药大学学报,2003,26(2)：6-7.
7.金楠楠,马堃.基于聚类及因子分析的功能失调性子宫出血中医证候要素研究[J].中国中药杂志,2008,33(13)：1622-1625.
8.王阶,邢雁伟等.复杂系统熵聚堆方法对1069例冠心病心绞痛证候要素提取和应证组合规律研究[J].中国中医基础医学杂志.2008,14(3)：211.
9.金香兰,张允岭等.运用因子分析探讨原发性高血压病证候要素[J].北京中医药大学学报.2011,34(2)：131.
10.王阶,李军,姚魁武等.冠心病心绞痛证候要素和冠脉病变的Logistic回归分析[J].辽宁中医杂志,2007,34(9)：1209-1211.
11.王天芳等.基于文献研究的中医证候要素研究概况.全国第十二次中医诊断学术年会论文集：271-274.
12.张启明,王永炎,张志斌等.外感病因中证候要素的提取[J].山东中医药大学学报,2005,29(5)：339-341.
13.郭蕾,王永炎,张俊龙等.关于证候因素的讨论[J].中国中西医结合杂志,2004,24(7)：643-644.
14.闫川慧,张俊龙,郭蓄等.颤振中医治疗方案的文献研究[J].辽宁中医杂志,2010(8)：1464-1465.
15.张志斌,王永炎,王志国.辫识证候要素在突发性公共卫生事件中的作用[J].北京中医药大学学报,2005,28(6)：4-7.
16.衰小琴,李玉玲.多囊卵巢综合征中医证候的现代文献研究[J].辽宁中医药大学学报2010,12(5)：39-40.
17.王天芳,于春光,等.抑郁症中医证候及证候要素分布特点的文献研究[J].中医杂志,2006,47(9)：691-693.
18.李志更,王天芳,赵燕,等.慢性肾功能衰竭常见证候与证候要素的现代丈献分析比较[J].中华中医药学刊,2007,25(1)：52-53.
19.蔡辉,毛静远.慢性心力衰竭中医辨证规律的文献分析[J].四川中医.2011,29(7)：22.
20.周景想,唐明等.2029例冠心病心绞痛中医证候特点及组合规律分析[J].中国中西医结合杂志.2011,31(6)：753.
21.申春悌,陆岩等.高血压病中医证候要素提取和命名的方法学研究[J].南京中医药大学学报.2010,26(5)：335.
22.马宏博,司国民等.血管性痴呆中医证候分布规律文献分析[J].世界中西医结合杂志.2012,7(3)：185.
23.张俊清,张军平.病毒性心肌炎中医证候要素文献研究[J].中医杂志.2011,52(13)：1141.
24.杨剑,李风森等.支气管哮喘中医证候要素提取的文献研究[J].中国民族民间医药：22.
25.孙俊波,赵璐等.基于文献的肺炎中医证候要素组合规律研究[J].中医杂志.2012,53(13)：1137.
26.陈剑明,张声生.基于经验辨证的溃疡性结肠炎常见证候及证候要素的临床研究[J].北京中医药,2011,30(6)：418.
27.陈剑明,张声生.非酒精性脂肪性肝病常见中医证候类型及证候要素的现代文献研究[J].中西医结合肝病杂志,2012,22(1)：51.
28.丁霞,师宁等.反流性食管炎中医证候分布特点的文献研究[J].中华中医药杂志(原中国医药学报).2012,27(4)：1174.
29.黎元元,高思华.基于专家观点的糖尿病证候要素提取文献分析[J].现代中西医结合杂志.2012,21(6)：571.
30.鱼浚镛,田金洲.基于中医文献的抑郁症常见证候及证候要素分布特点的研究[J].天津中医药.2012,29(3)：299.
31.王强.“证素”学说值得商榷[J].环球中医药.2011,4(1)：52-53.
1.郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002：：32-392
2.王永炎,张启明,张志斌.证候要素及其靶位的提取[J].山东中医药大学学报,2006,30(1)：1-4.
3.王永炎.完善辨证方法体系的建议[J].中医杂志,2004,45(10)：729-731.
4.王永炎,张启明,张志斌.证候要素及其靶位的提取[J].山东中医药大学学报,2006,30(1)：1-4.
5.王天芳等.基于文献研究的中医证候要素研究概况.全国第十二次中医诊断学术年会论文集：271-274.
1.中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2006年2月修订).现代消化及介入诊疗,2007,12(4)：266-268.
2.张文彤SPSS11统计分析教程(高级篇)[M].北京希望电子出版社,2002, 6：192-200.
3.郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002：：32-392.
4.国家中医药管理局.中医病证诊断疗效标准[S].南京：南京大学出版社,1995：6-11
5.李方玲.体检人群中脂肪肝患者的症状规律与舌象特征研究[D].北京：北京中医药大学,2006：35-50
1.谢晨.浅谈脂肪肝的降脂治疗[J].医学与哲学(临床决策论坛版),2007,28(1)：18.
2. RameshS,SanyalAJ.Evaluation andmagnagement of nonalcoholic steatohepatitis. JHepato, 2005,42:2-12.
3.杨惠民,盛彤,韩丽蓓.调脂通脉颗粒治疗老年高脂血症痰瘀证的临床研究[J].中华中医药杂志,2005, 20(4)：247-248.
4.范建高,方继伟,陆元善等.U230芯片动态观察非酒精性脂肪性肝病大鼠肝脏基因表达[J].中华肝脏病杂志.2005, 13(8)：597-601.
5.顾小红,张云东,冯爱娟.解偶联蛋白-2在大鼠非酒精性脂肪肝中的表达[J].世界华人消化杂志,2005,13(19)：2310-2313.
6.苏冬梅,李健等.健脾疏肝方对非酒精性脂肪性肝炎大鼠ADP、TNF-a的影响[J].北京中医药大学学报,2011,34(12)：826-829.
7.诸葛丽等.调肝化浊解毒方对N A S H大鼠的治疗作用及其机理研究[J].江苏中医药,2012,44(5)：71-74.
8.矫燕.脂肪肝与高血脂的关系[J].中国临床医药研究杂志,2008.(184)：64.
9.张有,江徐勤,袁飞.脂肪肝患者血脂及胆碱酯酶测定的临床意义[J].实验与检验医学,2008,26(5)：557-558.
10. ASPICHUETA P, PEREZ AGOTE B, PEREZ S, et al.Impaired response of VLDL lipid and ApoB secretion to endotoxin in the fasted rat liver[J]. Endotoxin Res,2006,12(3): 181-192.
11. WEISBERG S P, MCCANN D, DESAI M, et al. Obesity is associated with macrophage accumulation in adipose tissue[J]. J ClinInvest,2008,112(12):1796-1808.
12.李宏涛,陈国民.D-氨基半乳糖研究的回顾和展望[J].肝脏,2004, 9(3)：209.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |